Despite advances in understanding Burkitt Lymphoma (BL), global survival gaps still exist. Novel insights into biomarkers have emerged with novel genomic analysis and new treaments such as targeted therapies with reduced toxicities have led to tailored therapies. However, survival disparities still persist especially in resource-limited settings where globally, most BL patients live, and among patients with relapsed/refractory Burkitt Lymphoma (R/R BL). BL is a rapidly-growing aggressive B-cell lymphoma classified into endemic, sporadic, or immunodeficiency-associated BL based on epidemiological features. Recent genomic and epidemiological studies distinguish Epstein-Barr virus (EBV)-positive and EBV-negative BL. In high-income countries (HICs), BL is 95% curable with early detection, intensive multi-agent chemotherapy, and antibody-based therapy. In contrast, survival in Sub-Saharan Africa (SSA), survival rarely exceeds 50%, reflecting diagnostic delays, high rates of treatment abandonment, and limited access to chemotherapy. Approximately 95% of EBV-positive BL predominate in pediatric SSA patients; in North Africa and Latin America, EBV is detectable in 40%-70% of cases. In Asia, reported EBV positivity varies between 20%-80%. Among individuals with HIV infection, 40%-70% of BL-positive patients are EBV positive. There is a strong correlation between P. falciparum, EBV infection, and BL. underlying the fact that some immune mechanisms at high risk to tolerate repeated malaria exposure and severe infections. Immune mechanisms in primary infection with EBV seem to confer protection against severe P. falciparum while increasing long-term BL risk among survivors, with some parasitic strains more oncogenic than others. The paradoxical interplay between infection with P. falciparum and BL suggests that BL develops in children who are otherwise resistant to severe malaria, with BL risk becomes significant only after a high number of repeated infections (>50) and continues to increase with additional exposure in malaria-resistant children which shows that P. falciparum is a critical driver of BL pathogenesis by modulating EBV. Althogh EBV persists silently in memory B-cells (latency 0), malaria-driven antigenic stimulation causes these cells to remember the germinal cells (GCs) thus reactivating EBV growth program (latency III) resulting in full protein expression, virion production, and shedding. Moreover, P. falciparum directly stimulates the proliferation of infected B-cells while at the same time, suppressing T-cell responses that normally control EBV. These processes significantly increase EBV viral load and shedding, explaining why children with BL have 5 to 13 times higher antibody titer against both pathogens than healthy persons. The pathogen interaction represents an evolutionary trade-off in which co-infection confers survival advantage to children and enhanced transmission of both pathogens. Early EBV infection in the first year of life provides a survival advantage against malaria-associated mortality in regions where malaria is endemic. EBV derived BH RF1/vIL-10 modulates host immune responses dampening excessive inflammation associated with severe malaria and reducing mortality, an effective immunomodulation that benefits both the host and P. falciparum pathogen. Germline susceptibilty to BL has been observed in rare inborn errors of immunity (IEI) including X-linked lympho-proliferative disease, X-MEN syndrome, ataxia telangiectasia, and Williams-Beuren syndromes. Germline variants that reduce malaria risk, such as sickle-cell trait and variants at ABO locus, are associated with decreased BL risk. The present analytical study underscores the importance of understanding the pathogenesis of BL, accurate diagnosis, the underlying genomics, and providing more accessible treatments in resource-limited regions in order to close the survival gaps in BL as BL is a highly curable disease with early detection.